Stock Scorecard



Stock Summary for Praxis Precision Medicines Inc (PRAX) - $37.70 as of 9/12/2025 9:19:21 PM EST

Total Score

8 out of 30

Safety Score

39 out of 100

Currently on the following lists
None
Tim's Recommendation
Avoid

Growth List Algorithm Criteria for PRAX

Positive Quarterly and Annual earnings growth
P/E ratio less than Industry P/E Ratio
P/E ratio less than Sector P/E Ratio
P/E ratio that is half the Annual earnings growth rate (or less)
Positive net cash position the past year and most recent quarter
Equity to debt ratio greater than 0.75 for past year and most recent quarter
Positive net income past year and 12 trailing months
Free cash flow ratio greater than 0 and less than 10

Small Cap List Algorithm Criteria for PRAX

Revenue growing by at least 20% average per year over the last 5 years
Market Capitalization under 2 billion
Price to Sales (P/S) ratio 12 trailing months less than Industry P/S ratio twelve trailing months
Price to Sales (P/S) ratio 12 trailing months less than Sector P/S ratio twelve trailing months
Net Income past year > Net Income prior year OR Net Income 12 trailing months > Net Income prior year OR Net Income 12 trailing months > Net Income past year

Dividend List Algorithm Criteria for PRAX

Declared an ex-dividend date
Forward annual dividend rate greater than 2
Positive net cash position the past year and most recent quarter
Equity to debt ratio greater than 0.75 for past year and most recent quarter
Current ratio most recent quarter greater than 2
Cash Flow per Share greater than Trailing Dividend Rate

Bonus Criteria for PRAX

P/E ratio less than five-year Average P/E ratio
Last Price to 52 Week Low Ratio Less Than 1
Total Cash Per Share > Last Day Price
P/S Ratio < 1
P/B Ratio < 1

Safety Rating Criteria for PRAX (39 out of 100)

Stock Price Rating (Max of 10) 8
Historical Stock Price Rating (Max of 10) 10
Stock Price Trend (Max of 10) 1
Book Value (Max of 10) 6
Book Value to Price (Max of 10) 0
Analyst Buy Ratings (Max of 5) 5
Analyst Strong Buy Ratings (Max of 5) 4
Dividend Yield Percentage (Max of 10) 0
Operating Margin (Max of 10) 0
Trading Volume (Max of 10) 5
Price to Earnings (Max of 10) 0
Geopolitical Risk Adjustment (Always 0 for USA or a Negative Number for Non-USA) 0

Latest News for for PRAX

Bragar Eagel & Squire, P.C. Is Investigating Praxis, Align, Lantheus, and Spirit and Encourages Investors to Contact the Firm - ( FLYY ) , Align Technology ( NASDAQ:ALGN ) 9/4/2025 11:54:00 AM
Praxis Precision Medicines to Participate in Upcoming Fireside Chat - Praxis Precision Medicine ( NASDAQ:PRAX ) 8/29/2025 12:00:00 PM
Praxis Precision Medicines to Participate in Upcoming Fireside Chat 8/29/2025 12:00:00 PM
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Praxis Precision Medicines, Inc. - PRAX - Praxis Precision Medicine ( NASDAQ:PRAX ) 8/25/2025 4:13:00 PM
PRAXIS ALERT: Bragar Eagel & Squire, P.C. is Investigating Praxis Precision Medicines, Inc. on Behalf of Praxis Stockholders and Encourages Investors to Contact the Firm - Praxis Precision Medicine ( NASDAQ:PRAX ) 8/23/2025 1:32:00 PM
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Praxis Precision Medicines, Inc. - PRAX - Praxis Precision Medicine ( NASDAQ:PRAX ) 8/21/2025 6:16:00 PM
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Praxis Precision Medicines, Inc. - PRAX - Praxis Precision Medicine ( NASDAQ:PRAX ) 8/9/2025 3:33:00 PM
Praxis Precision Medicines to Participate in Upcoming Fireside Chat 8/5/2025 10:09:00 PM
Praxis Precision Medicines, Inc. Investors: Company Investigated by the Portnoy Law Firm - Praxis Precision Medicine ( NASDAQ:PRAX ) 8/5/2025 9:50:00 PM
Praxis Precision Medicines to Participate in Upcoming Fireside Chat - Praxis Precision Medicine ( NASDAQ:PRAX ) 8/5/2025 12:24:00 AM

Financial Details for PRAX

Company Overview

Ticker PRAX
Company Name Praxis Precision Medicines Inc
Country USA
Description Praxis Precision Medicines, Inc., a clinical-stage biopharmaceutical company, develops therapies for central nervous system disorders characterized by neuronal imbalance. The company is headquartered in Cambridge, Massachusetts.
Sector Name HEALTHCARE
Industry Name BIOTECHNOLOGY
Most Recent Quarter 6/30/2025
Next Earnings Date 11/5/2025

Stock Price History

Last Day Price 37.70
Price 4 Years Ago 295.50
Last Day Price Updated 9/12/2025 9:19:21 PM EST
Last Day Volume 496,484
Average Daily Volume 506,437
52-Week High 91.83
52-Week Low 26.70
Last Price to 52 Week Low 41.20%

Valuation Measures

Trailing PE N/A
Industry PE 21.34
Sector PE 40.86
5-Year Average PE -20.52
Free Cash Flow Ratio 5.04
Industry Free Cash Flow Ratio 13.20
Sector Free Cash Flow Ratio 29.37
Current Ratio Most Recent Quarter 6.31
Total Cash Per Share 7.48
Book Value Per Share Most Recent Quarter 19.21
Price to Book Ratio 2.10
Industry Price to Book Ratio 28.96
Sector Price to Book Ratio 32.27
Price to Sales Ratio Twelve Trailing Months 109.06
Industry Price to Sales Ratio Twelve Trailing Months 44.01
Sector Price to Sales Ratio Twelve Trailing Months 19.72
Analyst Buy Ratings 8
Analyst Strong Buy Ratings 3

Share Statistics

Total Shares Outstanding 21,049,600
Market Capitalization 793,569,920
Institutional Ownership 113.11%

Dividends

Ex-Dividend Date N/A
Previous Dividend Amount 0.0000
Current Dividend Amount 0.0000
Total Years Dividend Increasing N/A
Trailing Annual Dividend Rate 0.00
Trailing Annual Dividend Yield 0.00%
Forward Annual Dividend Rate 0.00
Forward Annual Dividend Yield 0.00%
5-Year Dividend Payments Count 0
3-Year Average Dividend Yield 0.00%
5-Year Average Dividend Yield 0.00%
1-Year Dividend Growth Rate Percentage 0.00%
3-Year Dividend Growth Rate Percentage 0.00%
5-Year Dividend Growth Rate Percentage 0.00%
All-Time Dividend Growth Rate Percentage 0.00%
Dividend Payout Ratio N/A

Income Statement

Quarterly Earnings Growth YOY 0.00%
Annual Earnings Growth -48.30%
Reported EPS 12 Trailing Months -12.40
Reported EPS Past Year -6.60
Reported EPS Prior Year -10.27
Net Income Twelve Trailing Months -251,012,000
Net Income Past Year -182,819,000
Net Income Prior Year -123,277,000
Quarterly Revenue Growth YOY 1,349.00%
5-Year Revenue Growth 0.00%
Operating Margin Twelve Trailing Months -3,498.00%

Balance Sheet

Total Cash Most Recent Quarter 157,415,000
Total Cash Past Year 215,372,000
Total Cash Prior Year 81,300,000
Net Cash Position Most Recent Quarter 157,415,000
Net Cash Position Past Year 215,372,000
Long Term Debt Past Year 0
Long Term Debt Prior Year 0
Total Debt Most Recent Quarter 0
Equity to Debt Ratio Past Year 1.00
Equity to Debt Ratio Most Recent Quarter 1.00
Total Stockholder Equity Past Year 445,450,000
Total Stockholder Equity Prior Year 69,669,000
Total Stockholder Equity Most Recent Quarter 404,224,000

Free Cash Flow

Free Cash Flow Twelve Trailing Months -191,492,000
Free Cash Flow Per Share Twelve Trailing Months -9.10
Free Cash Flow Past Year -131,757,000
Free Cash Flow Prior Year -111,186,000

Options

Put/Call Ratio 0.00
Has Options Options Chain
Liquidity Rating

Technical Analysis

Yahoo Finance Chart Yahoo Finance Chart
MACD -2.04
MACD Signal -1.47
20-Day Bollinger Lower Band 33.46
20-Day Bollinger Middle Band 45.22
20-Day Bollinger Upper Band 56.99
Beta 2.62
RSI 32.45
50-Day SMA 55.97
150-Day SMA 41.19
200-Day SMA 65.06

System

Modified 9/11/2025 7:54:25 AM EST